scholarly journals EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

2021 ◽  
Vol 16 (11) ◽  
pp. 1793-1797
Author(s):  
Sophie Stock-Martineau ◽  
Frances A. Shepherd
Sign in / Sign up

Export Citation Format

Share Document